DEA moves to fight shortages of medicines needed for Covid-19 patients
The Drug Enforcement Administration is taking steps to permit increased production and importation of various medicines that are in short supply and needed for Covid-19 patients who are placed on ventilators.
The agency is increasing production quotas by 15% for several controlled substances, including fentanyl, morphine, hydromorphone, codeine, ephedrine, and pseudoephedrine, as well as certain so-called intermediates that are essential to producing these medicines. The DEA also plans to approve increased imports of ketamine, diazepam, midazolam, lorazepam, and phenobarbital (here is the order).
Read Original Article: DEA moves to fight shortages of medicines needed for Covid-19 patients »
